Envudeucitinib vs Fadeucravacitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

Envudeucitinib

Developed by Alumis and partners

Phase 3 in Psoriasissmall molecule
Reliable signal

NCT06586112 · Phase 3 · completed

Participants were randomized and blinded across drug, placebo, and active-comparator arms. A much larger share of patients on envudeucitinib achieved high levels of skin clearance than on placebo, with a highly significant difference.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2027 · NCT05739435 (registry estimate)

Reported efficacy

To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo (16 weeks): PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all) (met)

Result source: NCT06586112

Fadeucravacitinib

Developed by Beijing InnoCare Pharma Tech Co.

Phase 3 in Psoriasissmall molecule
Partial signal

NCT06109818 · Phase 2 · completed

The trial randomized 129 participants to two ICP-488 dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical psoriasis measure PASI 75 at Week 12, but the registry does not report whether the comparison was met.

Figures via dermatology news coverage of the sponsor's announcement; no peer-reviewed publication or registry results yet. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 12. (Baseline up to Week 12): PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved (met)

Result source: NCT06109818

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnvudeucitinibFadeucravacitinib
PASI 7556.4% vs 0%+56.4 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 64.1% vs 0% 40mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 33.3% vs 0% 20mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
  • 56.4% vs 0% 20mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 19.4% vs 0% 10mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
—Trial running · NCT06842199
PASI 90—Not posted · NCT06588738—Trial running · NCT06842199
PASI 100—Not posted · NCT06588738—Trial running · NCT06842199
sPGA 0/153.8% vs 7.9%+45.9 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 59% vs 7.9% 40mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 38.9% vs 7.9% 20mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
  • 48.7% vs 7.9% 20mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 16.7% vs 7.9% 10mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
—Trial running · NCT06842199
DLQI, change—Not posted · NCT06588738—Trial running · NCT06842199

PASI 75

Envudeucitinib
56.4% vs 0%+56.4 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 64.1% vs 0% 40mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 33.3% vs 0% 20mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
  • 56.4% vs 0% 20mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 19.4% vs 0% 10mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
Fadeucravacitinib
—Trial running · NCT06842199

PASI 90

Envudeucitinib
—Not posted · NCT06588738
Fadeucravacitinib
—Trial running · NCT06842199

PASI 100

Envudeucitinib
—Not posted · NCT06588738
Fadeucravacitinib
—Trial running · NCT06842199

sPGA 0/1

Envudeucitinib
53.8% vs 7.9%+45.9 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 59% vs 7.9% 40mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 38.9% vs 7.9% 20mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
  • 48.7% vs 7.9% 20mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 16.7% vs 7.9% 10mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
Fadeucravacitinib
—Trial running · NCT06842199

DLQI, change

Envudeucitinib
—Not posted · NCT06588738
Fadeucravacitinib
—Trial running · NCT06842199
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Fadeucravacitinib
PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved NCT06109818 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Envudeucitinib: 4 of 4 rows · Fadeucravacitinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEnvudeucitinib
Dropout rate
10.3%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
15.4%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
7.5%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
16.7%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.6%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
2.6%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
5.6%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
Serious AEs
0%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
2.6%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
7.7%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
0%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
2.8%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
40mg BIDa
headache 7.7% (placebo 5.3%)
nasopharyngitis 7.7% (placebo 7.9%)
upper respiratory tract infection 7.7% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
40mg QD
headache 10.3% (placebo 5.3%)
acne 5.1% (placebo 0%)
upper respiratory tract infection 5.1% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
20mg BID
headache 7.7% (placebo 5.3%)
cough 5.1% (placebo 0%)
diarrhea 5.1% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
20mg QD
headache 5.6% (placebo 5.3%)
upper respiratory tract infection 5.6% (placebo 0%)
acne 0% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
10mg QD
diabetes mellitus 5.6% (placebo 0%)
nasopharyngitis 5.6% (placebo 7.9%)
upper respiratory tract infection 5.6% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Envudeucitinib

PASI 75 56.4% (n=39) vs 0% (n=38) placebo @ 12wk40mg QD
responder rate · % of participants
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
64.1% (n=39) vs 0% (n=38) placebo @ 12wk40mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
33.3% (n=36) vs 0% (n=38) placebo @ 12wk20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
56.4% (n=39) vs 0% (n=38) placebo @ 12wk20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
19.4% (n=36) vs 0% (n=38) placebo @ 12wk10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
sPGA 0/1 53.8% (n=39) vs 7.9% (n=38) placebo @ 12wk40mg QD
responder rate · % of participants
NCT05600036 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
show 4 more results
59% (n=39) vs 7.9% (n=38) placebo @ 12wk*40mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
38.9% (n=36) vs 7.9% (n=38) placebo @ 12wk*20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
48.7% (n=39) vs 7.9% (n=38) placebo @ 12wk*20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted
16.7% (n=36) vs 7.9% (n=38) placebo @ 12wk*10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Envudeucitinib's landscape · Fadeucravacitinib's landscape